Now we know what “baby leads” are.

The New York attorney general joined a whistleblower lawsuit accusing an AstraZeneca unit of defrauding Medicaid by obtaining confidential data on infants in order to boost sales of a key medicine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • As a writer in the field of substance abuse and treatment for over 20 years I have watched state and federal litigation against pharma for assorted offences continue to escalate, some fines now in the $billions. It really is true that some pharmaceutical industry players consider criminal behavior a normal mode of business and the fines levied when they’re caught just a normal business expense. This will probably never change until the feds and states can actually send offenders to jail where they belong, where similar offenders in any other industry would be sent. The recent Mallinckrodt debacle shows how toothless some of our laws can be. One wonders if it will get even worse under the new federal administration.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy